Bonello William 4
4 · NEOGENOMICS INC · Filed Nov 29, 2021
Insider Transaction Report
Form 4
Bonello William
VP, Investor Relations
Transactions
- Sale
Common Stock
2021-11-24$37.13/sh−25,000$928,250→ 15,473 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-11-24−25,000→ 45,370 totalExercise: $8.03Exp: 2023-02-26→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2021-11-24$8.03/sh+25,000$200,750→ 40,473 total
Holdings
- 35,727
Stock Option (Right to Buy)
Exercise: $7.52Exp: 2022-04-28→ Common Stock (35,727 underlying) - 24,619
Stock Option (Right to Buy)
Exercise: $53.17Exp: 2028-03-02→ Common Stock (24,619 underlying) - 37,514
Stock Option (Right to Buy)
Exercise: $28.33Exp: 2027-03-02→ Common Stock (37,514 underlying) - 41,167
Stock Option (Right to Buy)
Exercise: $19.60Exp: 2024-03-01→ Common Stock (41,167 underlying)
Footnotes (6)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]On April 28, 2017, Mr. Bonello was granted 100,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- [F3]On February 26, 2018, Mr. Bonello was granted 120,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- [F4]On March 1, 2019, Mr. Bonello was granted 41,167 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F5]On March 2, 2020, Mr. Bonello was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F6]On March 2, 2021, Mr. Bonello was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date.